Profile data is unavailable for this security.
About the company
Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.
- Revenue in USD (TTM)5.15m
- Net income in USD-3.69m
- Incorporated1994
- Employees6.00
- LocationImmuron Ltd62 Lygon Street, Level 3MELBOURNE 3053AustraliaAUS
- Phone+61 39824-5254
- Fax+61 39822-7735
- Websitehttps://www.immuron.com.au
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals Inc | 16.94m | -3.48m | 4.78m | 168.00 | -- | 1.22 | -- | 0.2822 | -2.20 | -2.20 | 10.65 | 2.30 | 1.23 | 3.26 | 5.78 | 100,815.50 | -25.26 | -29.32 | -34.95 | -40.47 | 37.68 | 36.22 | -20.54 | -32.35 | 2.05 | -- | 0.0146 | -- | 12.19 | -4.44 | 28.50 | -- | -17.24 | -- |
| 60 Degrees Pharmaceuticals Inc | 1.35m | -8.48m | 5.21m | 3.00 | -- | -- | -- | 3.85 | -23.04 | -23.04 | 2.93 | 4.32 | 0.1919 | 1.59 | 2.71 | 451,383.30 | -113.08 | -- | -148.26 | -- | 42.47 | -- | -589.17 | -- | 2.63 | -44.07 | 0.0342 | -- | 168.70 | -- | -111.48 | -- | -- | -- |
| Sunshine Biopharma Inc | 37.32m | -5.99m | 5.89m | 52.00 | -- | 0.226 | -- | 0.1577 | -2.03 | -2.03 | 10.74 | 5.31 | 1.21 | 2.09 | 10.12 | 717,764.30 | -19.47 | -68.65 | -23.80 | -89.02 | 33.01 | 32.79 | -16.06 | -81.12 | 2.09 | -209.95 | 0.00 | -- | 44.75 | 340.11 | -13.94 | -- | 370.33 | -- |
| LakeShore Biopharma Co Ltd | 88.99m | -14.47m | 6.63m | 573.00 | -- | 0.0462 | 0.9964 | 0.0745 | -0.7487 | -0.7487 | 4.64 | 3.48 | 0.427 | 0.5001 | 1.30 | 155,302.20 | -6.94 | -- | -15.95 | -- | 82.47 | -- | -16.26 | -- | 0.7452 | -2.63 | 0.453 | -- | 7.24 | -- | 76.93 | -- | -- | -- |
| CV Sciences Inc | 14.37m | -1.48m | 6.71m | 47.00 | -- | 4.36 | -- | 0.4669 | -0.008 | -0.008 | 0.078 | 0.0084 | 1.87 | 1.67 | 34.74 | 305,659.60 | -19.21 | -44.92 | -66.32 | -105.32 | 47.04 | 42.89 | -10.29 | -49.08 | 0.2125 | -2.02 | 0.3829 | -- | -1.87 | -21.80 | -177.18 | -- | -56.43 | -- |
| Immuron Ltd - ADR | 5.15m | -3.69m | 7.18m | 6.00 | -- | -- | -- | 1.39 | -0.6392 | -0.6392 | 0.8934 | -- | 0.5675 | 1.50 | 4.40 | -- | -40.62 | -27.84 | -49.64 | -30.60 | 65.39 | 70.18 | -71.58 | -182.34 | 4.19 | -- | 0.00 | -- | 48.63 | 23.67 | 24.81 | -- | -- | -- |
| Tian'an Pharmaceutical Co Ltd | 10.65m | 3.14m | 8.00m | -- | 0.0445 | 0.0097 | 2.20 | 0.7511 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
| cbdMD Inc | 19.19m | -4.38m | 8.51m | 42.00 | -- | 1.00 | -- | 0.4435 | -3.92 | -3.92 | 4.77 | 0.8104 | 1.83 | 2.83 | 18.96 | -- | -19.44 | -48.27 | -44.42 | -54.99 | 62.37 | 63.95 | -10.63 | -85.60 | 1.20 | -- | 0.00 | -- | -1.50 | -14.45 | 43.21 | -- | -32.56 | -- |
| Gelteq Ltd | 117.18k | -4.70m | 8.57m | 7.00 | -- | 0.7664 | -- | 73.13 | -0.4981 | -0.4981 | 0.0124 | 1.04 | 0.0078 | -- | 0.5155 | 16,740.08 | -31.47 | -17.38 | -40.60 | -19.16 | -- | -- | -4,011.74 | -4,507.46 | -- | -3.52 | 0.2106 | -- | -- | -- | -87.40 | -- | -- | -- |
| Biofrontera Inc | 37.17m | -17.57m | 9.09m | 92.00 | -- | -- | -- | 0.2445 | -1.84 | -1.84 | 4.07 | -0.2216 | 2.19 | 2.44 | 9.45 | 403,967.40 | -103.57 | -48.03 | -339.69 | -77.55 | 64.41 | 48.93 | -47.28 | -60.99 | 0.8033 | -47.48 | 2.37 | -- | 9.54 | 7.35 | 11.78 | -- | -35.51 | -- |
| Cuprina Holdings (Cayman) Ltd | 23.99k | -2.24m | 9.42m | 14.00 | -- | 1.55 | -- | 392.50 | -0.1232 | -0.1232 | 0.0013 | 0.283 | 0.0049 | 13.39 | 0.7976 | 1,713.68 | -44.56 | -- | -131.50 | -- | -69.27 | -- | -9,194.46 | -- | 3.58 | -306.25 | 0.0244 | -- | -52.05 | -- | -39.39 | -- | -- | -- |
| Integrated Biopharma Inc | 53.43m | 672.00k | 9.94m | 153.00 | 15.10 | 0.4849 | 10.04 | 0.186 | 0.0212 | 0.0212 | 1.71 | 0.6597 | 2.07 | 4.45 | 12.77 | 349,183.00 | 2.60 | 9.98 | 3.28 | 13.68 | 9.75 | 10.74 | 1.26 | 4.58 | 1.92 | -- | 0.0072 | -- | 8.02 | 0.5933 | 482.30 | -30.67 | -0.8556 | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 10.05m | 233.00 | 0.0687 | 0.0011 | 2.60 | 0.142 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
Data as of Feb 11 2026. Currency figures normalised to Immuron Ltd's reporting currency: US Dollar USD
0.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 30 Sep 2025 | 19.56k | 0.24% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 18.25k | 0.22% |
| XTX Markets LLCas of 30 Sep 2025 | 17.97k | 0.22% |
| RhumbLine Advisers LPas of 30 Sep 2025 | 5.94k | 0.07% |
| UBS Securities LLCas of 31 Dec 2025 | 4.14k | 0.05% |
| BNP Paribas Financial Marketsas of 30 Sep 2025 | 1.31k | 0.02% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 10.00 | 0.00% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
